Home / Guidelines / Regulation of biologicals in Colombia

Regulation of biologicals in Colombia Posted 20/04/2018

Since the introduction of Decree 1782 Colombia has been moving towards a new regulatory landscape for biologicals (productos bioterapéuticos) and similar biotherapeutic products (productos bioterapéuticos similares) in the country [1].

Decree 1782 was signed by Colombian President Juan Manuel Santos Calderón, in September 2014. The decree allows for three different routes for biologicals:

Complete dossier: for new biologicals
In place for over 20 years. Includes five modules for evaluation: 1. Administrative; 2. Summary; 3. Quality; 4. Non-clinical; and 5. Clinical.

Comparability approach: for drugs that are not new, but that are not yet sufficiently known
Comparability based on analytical characterization/studies. Uses a step-by-step process of clinical and non-clinical comparative studies designed for molecules with expired patents where molecules are compared against a reference product. Also includes five modules, however, in the comparability approach, modules 3−5 all include comparability exercises, whilst the clinical assessment required in module 5 is reduced.

Abbreviated comparability approach: short route for well-known drugs and drugs with fully characterized chemical substances
Based on the step-wise concept, the European Medicines Agency and the US Food and Drug Administration’s biosimilar guidelines recommend that clinical confirmatory studies are not always needed to demonstrate biosimilarity between reference and biosimilar products. Similarly, Colombia has developed this pathway for molecules where the reference product is sufficiently characterized, has well-defined and well-documented safety and efficacy profile, has strong clinical experience data and has strong pharmacovigilance evidence. The module system resembles that of the comparability approach but for module 5, only pharmacokinetics and pharmacodynamics data may be required.

The pathway to be followed will depend on the biological/similar biotherapeutic product in question.

Editor’s comment
This article for GaBI Online is a summary of the full article published in GaBI Journal.

If you would like to receive a copy* of the GaBI Journal article, please send us an email.

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index, and more.

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here.

Related article
Colombian guidelines for productos bioterapéuticos similares

Reference
1. Sierra Esteban FJ, García Cortes JA. Regulations for biotherapeutics approval in Colombia. Generics and Biosimilars Initiative Journal (GaBI Journal). 2018;7(1):26-8. doi:10.5639/gabij.2018.0701.006

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Comments (0)